Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Columbia University Medical Center
630 West 168th StreetPresbyterian Hospital Building, PH-17
New York, New York, United States
Email Phone Web
The Division of Pediatric Hematology at Columbia University is committed to outstanding patient care, research, and education. Our mission is three-fold: 1) to provide personalized high quality, comprehensive care of children and adolescents with hematologic disorders; 2) to promote advances in biomedical research in the management of hematological conditions; and 3) to foster academic experience, education and training. Our Faculty provides expert inpatient and outpatient services from early diagnosis to continuing care and follow up of a wide spectrum of blood-related diseases.
Our newly established St. Giles Comprehensive Sickle Cell and Thalassemia Center provides comprehensive, family-centered care to pediatric patients with sickle cell disease and thalassemia. The Center is focused on guaranteeing consistent provision of the best evidence-based treatments, assuring early recognition of risks of preventable complications and providing dependable support for effective family and patient self-management. The program provides a variety of services to the communities of Harlem, Northern Manhattan, and the tri-state area, including newborn screening in sickle cell disease, stroke prevention, chronic transfusion and iron-chelating therapy, pain management, community outreach, and patient education programs.
+myBinderRelated Content
-
John F. Tisdale, MDJohn F. Tisdale, MD graduated from the C...
-
Mount Sinai HospitalIn addition to dedicated treatment progr...
-
Santosh L. Saraf, MDDr. Santosh Saraf is an assistant profes...
-
Brigham and Women’s Sickle Cell Disease ClinicEach person with sickle cell disease is ...
-
Diving into the genetics of Sickle cell diseaseIn recent years, genetics has become a h...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
